Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination

Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is currently being tested as an adjuvant treatment modality for resected locoregional metastatic (stage III) melanoma. Based on its mechanism of action, DC vaccination might potentiate the clinical effi...

Full description

Bibliographic Details
Main Authors: Wouter W. van Willigen, Martine Bloemendal, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Rutger H.T. Koornstra, Astrid A.M. van der Veldt, John B. A. G. Haanen, Steve Boudewijns, Gerty Schreibelt, Winald R. Gerritsen, I. Jolanda M. de Vries, Kalijn F. Bol
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
melanoma
immunotherapy
adjuvant
dendritic cell
vaccination
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1738814

Internet

http://dx.doi.org/10.1080/2162402X.2020.1738814

Similar Items